Business
Quest PharmaTech announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists
Quest PharmaTech announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 20...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n \n \n \n Quest PharmaTech announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n TSX Venture: QPT\n \n \n \n \n EDMONTON, AB\n \n ,\n \n June 1, 2021\n \n /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) (\"Quest\" or the \"Company\") announces that clinical investigators working with OncoQuest Pharmaceuticals, Inc. (\"OQP\") lead clinical candidate oregovomab, will be making two presentations as part of the American Society of Clinical Oncology (ASCO) conference proceedings. OQP acquired oregovomab from OncoQuest Inc., one of the equity investee companies (45%) of Quest PharmaTech Inc.\n \n \n The first presentation by Dr.\n \n Angeles Alvarez Secord\n \n , Principal Investigator and Associate Director of Clinical Research at Duke Cancer Institute of\n \n Duke University\n \n will update the research community on progress with the ongoing FLORA 5 phase III clinical study of front-line carboplatin-paclitaxel-oregovomab chemotherapy.  This double blind and placebo controlled multinational trial is currently accruing patients at centers in the US,\n \n Canada\n \n ,\n \n Europe\n \n and\n \n Asia\n \n and is adding additional centers and participating geographies.  This study seeks to confirm the observations of Brewer et al in Gynecologic Oncology 2020 that demonstrated how oregovomab in combination with carboplatin and paclitaxel could dramatically improve both progression free and overall survival relative to chemotherapy in the absence of incremental toxicity.\n \n \n The second oregovomab report at ASCO being presented by Dr.\n \n Robert Holloway\n \n , Medical Director of the Gynecologic Oncology Program at Florida Hospital is an abstract presentation of the results from the Phase\n \n 1b\n \n oregovomab clinical trial protocol ORE-QPT-003H.  The report titled, \"Final survival follow up and translational associations using interval indirect immunization with oregovomab (O) ...